J
Joao Victor Machado Alessi
Researcher at Harvard University
Publications - 67
Citations - 574
Joao Victor Machado Alessi is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 22 publications receiving 134 citations. Previous affiliations of Joao Victor Machado Alessi include Adma & University of São Paulo.
Papers
More filters
Journal ArticleDOI
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
Joao Victor Machado Alessi,Biagio Ricciuti,Liam F. Spurr,Hersh Gupta,Yvonne Y. Li,Yvonne Y. Li,Carolyn Glass,Mizuki Nishino,Andrew D. Cherniack,Andrew D. Cherniack,James Lindsay,Bijaya Sharma,Kristen D. Felt,Scott J. Rodig,Michael Cheng,Lynette M. Sholl,Mark M. Awad +16 more
TL;DR: In this paper, the authors collected clinicopathologic and genomic data from patients with NSCLC who underwent targeted next-generation sequencing at the Dana-Farber Cancer Institute and characterized the presence or absence of muts across a set of six SWI/SNF genes.
Journal ArticleDOI
Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives
TL;DR: The role of adjuvant chemotherapy in these patients remains debatable since it is known that only a small fraction of patients will derive meaningful benefit from this treatment whilst the majority will be exposed to significant and unnecessary chemotherapy-related toxicities, in particular the elderly and frail as mentioned in this paper.
Journal ArticleDOI
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
Joao Victor Machado Alessi,Biagio Ricciuti,S. Alden,Arrien A. Bertram,Jessica J. Lin,Mustafa Sakhi,Mizuki Nishino,Victor Vaz,James Lindsay,Madison M Turner,Kathleen Pfaff,Bijaya Sharma,Kristen D. Felt,Scott J. Rodig,Scott J. Rodig,Justin F. Gainor,Mark M. Awad +16 more
TL;DR: In this paper, an unbiased recursive partitioning algorithm was used to investigate an optimal dNLR cut-off with respect to objective response rate (ORR) for patients with non-small cell lung cancer (NSCLC) receiving chemotherapy and immune checkpoint inhibitors.
Journal ArticleDOI
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
Alessio Cortellini,Alessio Cortellini,Biagio Ricciuti,Francesco Facchinetti,Joao Victor Machado Alessi,Deepti Venkatraman,F.G. Dall'Olio,Paola Cravero,Victor Vaz,Diego Ottaviani,Margarita Majem,A. Piedra,I. Sullivan,Karla A. Lee,Karla A. Lee,Giuseppe Lamberti,N. Hussain,James Clark,Anita Bolina,A. Barba,Jose Carlos Benitez,T. Gorria,L. Mezquita,Delphine Hoton,F. Aboubakar Nana,Benjamin Besse,Benjamin Besse,Mark M. Awad,David J. Pinato +28 more
TL;DR: In this article, the authors evaluated the association between prior antibiotic therapy (pATB) and concurrent ATB and overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in patients with non-small-cell lung cancer (NSCLC) treated with first-line chemo-immunotherapy at eight referral institutions.
Journal ArticleDOI
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
Xinan Wang,Biagio Ricciuti,Joao Victor Machado Alessi,Tom C. Nguyen,Mark M. Awad,Xihong Lin,Bruce E. Johnson,David C. Christiani +7 more
TL;DR: In this article, a study was conducted on 644 advanced non-small cell lung cancer (NSCLC) patients treated with ICI monotherapy between April 2013 and September 2020 at the Dana-Farber Cancer Institute and Brigham and Women's Hospital.